CJC-1295 (No DAC)

Overview

CJC-1295 (No DAC) binds to GHRH receptors on somatotroph cells in the anterior pituitary, triggering G-protein signaling cascades that increase intracellular cAMP and activate protein kinase A, leading to downstream regulation of GH synthesis and secretion. The four amino acid substitutions at positions 2, 8, 15, and 27 improve resistance to DPP-4 enzymatic cleavage, extending bioactivity relative to native GHRH(1-29) while preserving the pulsatile secretion profile that distinguishes it from DAC-conjugated analogs.

Researchers studying the GH axis have used CJC-1295 (No DAC) to examine pituitary somatotroph signaling, downstream IGF-1 dynamics, and pulsatile versus sustained GH secretion patterns in experimental settings. It has also been studied alongside ghrelin receptor agonists to investigate dual-pathway GH axis modulation.

Chemical Profile

Research Findings

GH Axis and IGF-1 Dynamics

CJC-1295 (No DAC) has been studied for its effects on endogenous GH secretion in a pulsatile pattern through GHRH receptor-mediated cAMP signaling. Early pharmacokinetic studies on CJC-1295 analogs have reported dose-dependent GH and IGF-1 responses in experimental settings. Published human pharmacokinetic data predominantly references the DAC-conjugated form; data specific to the No DAC formulation remains limited. Preclinical models have examined downstream changes in markers associated with collagen synthesis, tissue remodeling, and skeletal muscle dynamics in the context of GH–IGF-1 axis activation.

Areas of Research

• GH axis modulation and GHRH receptor signaling
• Pulsatile GH release dynamics modeling
• IGF-1 axis activity studies
• Dual-pathway GH secretagogue combination research

Research Use Only: This product is sold exclusively for laboratory and scientific research. It is not approved for human or veterinary use or consumption.

Disclaimer: All products distributed by Resolve Peptides are supplied exclusively for controlled laboratory and scientific research. They are not drugs, supplements, or therapies, and have not been approved by the FDA or any regulatory authority for human or veterinary use. These products are not intended for human or veterinary administration. Regulatory status of research peptides is subject to change; it is the responsibility of the researcher to verify current applicable regulations in their jurisdiction prior to purchase. Any references to biological effects are based solely on experimental and preclinical data.